In addition, other studies show anti-tumor effects of GSK-3β inhibition on prostate cancer cells in vitro, but these effects were predominantly attributed to modulating effects on the androgen-receptor axis [30, 31], or changes in cell cycle proteins [23]. This evidence concerns the gene GSK3B and neoplasm.